EGFR and hepatocellular carcinoma: Recently, Jin et al. (2021) found that lenvatinib and gefitinib had antitumor activity in HCC PDX with high expression of epidermal growth factor receptor (EGFR), and EGFR has been used as a biomarker to achieve a more informed patient stratification in clinical trials.